Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.66 |
| ▸ | TNKS | O95271 | 12/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.54 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176866 | 1.00 | PARP1 (0.66) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL31483746 | 0.88 | PARP1 (0.62) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL21072675 | 0.88 | PARP1 (0.62) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL21127777 | 0.81 | PARP1 (0.54) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL15042919 | 0.80 | PARP1 (0.42) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL1387263 | 0.80 | PARP1 (1.00) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL17829612 | 0.77 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL21072769 | 0.77 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL9671521 | 0.77 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL4313736 | 0.77 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2023-04-27 | — | — | US | disclosed |
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2023-04-27 | — | — | US | disclosed |
| CN-112174899-B | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-112174899-A | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2021-01-05 | — | — | CN | disclosed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-5401745-A | Cardiovascular disorders or hypotensive agents | MERCK & CO., INC. (US) | 1995-03-28 | — | — | US | disclosed |
| WO-1994021259-A1 | QUINAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130602-A1 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | CDC37, SI, DAD1 | PARP1 4316/4885TNKS 2943/4885TNKS2 3469/4885 |
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | PARP1 1371/4885TNKS 2301/4885TNKS2 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.